Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. New issue in AttgeNO
Mandate

New issue in AttgeNO

May 02, 2018 M&A

The Swedish pharmaceutical research company AttgeNO has performed a new issue of shares.

AttgeNO works on the development of new pharmaceuticals which expand blood vessels. Supernitro (PDNO) is a new, patented pharmaceutical candidate for treatment of acute and life-threatening high blood pressure in the lungs, which, can arise for example in connection with heart surgery and may result in death. The capital generated as a result of the new issue of shares is intended to give AttgeNO an opportunity to perform clinical Phase 1 studies during 2019.

AttgeNO was advised by partner Johan Winnerblad.

Related

Vinge advises Active Biotech in connection with rights issue

 Vinge advises Active Biotech AB (publ) in connection with a rights issue of approximately SEK 43 million.
November 29, 2024

Vinge advises ABGSC and SEB in connection with Europi’s inaugural issuance of green bonds

Vinge has advised the joint arrangers in connection with Europi Property Group AB (publ)’s (the "Company") inaugural issue of EUR 50 million senior unsecured green bonds within a framework of up to EUR 100 million. The bonds carry a floating interest rate of EURIBOR 3M + 5.00% and have a tenor of three years. The Company intends to apply for admission to trading of the new bonds on Nasdaq Transfer Market and the sustainable bond list of Nasdaq Stockholm.
November 29, 2024

Vinge advises Rieber & Søn in connection with its acquisition of Accept Försäkringsaktiebolag (publ)

 Accept, with headquarter in Stockholm, has been an innovator in the Swedish insurance market since its formation in 1998. The company was the first with offering loss of income insurance and has since offered products that complement the general insurance offering. Today, Accept delivers web-based insurance solutions customised for its offering.
November 21, 2024